Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PUVA-inactivated whole-cell Campylobacter jejuni vaccine
- Development stage
- Preclinical
- Lead developer
- Blue Collar Vaccines and Therapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PUVA-inactivated whole-cell Campylobacter jejuni vaccine is an investigational whole-cell bacterial vaccine designed to prevent Campylobacter jejuni infections, a leading cause of bacterial diarrhea worldwide. Developed by Blue Collar Vaccines and Therapeutics in collaboration with the Wake Forest School of Medicine and the Naval Medical Research Center, the vaccine utilizes psoralen (specifically the derivative 4-aminomethyl-4,5',8-trimethylpsoralen, or AMT) combined with ultraviolet A (UVA) irradiation to inactivate the bacteria. This PUVA inactivation process creates killed but metabolically active (KBMA) bacteria, which preserves the structural integrity of key surface antigens and enhances immunogenicity compared to traditional formalin inactivation methods. Preclinical studies in mouse models have demonstrated that the vaccine, particularly when adjuvanted with double-mutant heat-labile toxin (dmLT), elicits a robust humoral immune response with elevated serum IgG titers.
- Other names
- psoralen inactivated whole cell Campylobacter vaccinepsoralen-inactivated whole-cell Campylobacter jejuni vaccinepsoralen-inactivated whole-cell Campylobacter vaccine
Beyond the preview
Go deeper on PUVA-inactivated whole-cell Campylobacter jejuni vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PUVA-inactivated whole-cell Campylobacter jejuni vaccine.